Skip to content
Wednesday 19 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,743.35
+0.14%
DAX
26,091.33
-0.14%
CAC 40
8,501.91
-0.09%
STOXX 50
6,444.46
-0.37%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Monday 15 December 2025 8:09 am  |  Updated:  Monday 15 December 2025 2:52 pm

Hikma: FTSE 100 giant’s boss replaced by former chief after share price woes

By: Samuel Norman

Senior City Reporter

Add as a preferred source on Google
Hikma produces generic drugs
Myricx has developed a new platform for antibody-drug conjugates

The boss of FTSE 100 giant Hikma Pharmaceuticals will be replaced by the firm’s former top chief after the group’s share price dropped by nearly a quarter this year.

Riad Mishlawi has exited his role as chief executive at Hikma, with executive chairman Said Darwazah to step into the post with “immediate effect”.

It ends an over-20-year tenure at the company for Mishlawi, who served in the top role for his last two years.

Meanwhile, Darwazah steps back into the role he served in from July 2007 to February 2018 and from June 2022 to August 2023.

It follows the drug maker maintaining full-year revenue targets last month, but adding that core operating profit would come in at the lower end of expectations, between $730m and $750m (£555m-£570m).

Profit fell six per cent in the first half of the year to $373m.

Russ Mould, investment director at AJ Bell, said: “Things may not have got any worse since November’s disappointing update but it’s no shock to see Hikma Pharmaceuticals CEO Riad Mishlawi head for the exit.”

He added: “The company faces tough competition in the generic drugs space, but it also has been the master of its own downfall thanks to delays to a new UK manufacturing facility and issues in its supply chain.

“In this context it is not a surprise to see Mishlawi, who has served with the company for decades and the last two years as CEO, carry the can and move into retirement.”

Read more

Diageo boss ‘drastic’ Dave Lewis eyes £20m pay deal as 2,000 jobs slashed

Dave Lewis, former Tesco CEO, smiling in a supermarket aisle with products on shelves

Hikma’s revenue to slow in the years to come

Hikma compounded the bad news by telling investors that revenue was expected to grow at the “lower end” of its target – six to eight per cent over the next three years.

Core operating profit is only expected to increase by five to seven per cent, down from previous expectations of seven to nine.

Shares in Hikma plunged after the news, falling 14% from 1,522p to 1,771p.

Shares in the firm are down nearly 25 per cent for the year-to-date.

Mishlawi said: “I’d like to thank Said and all my Hikma colleagues. 

“It has been an honour to work alongside you and, as I move into retirement, I wish you continued growth and every success.”

Darwazah said: “I would like to thank Riad for his contributions over his long career at Hikma and we wish him well for the future. 

“I look forward to continuing to work closely with Hikma’s Executive Committee and with Khalid in his expanded role to deliver on our strategic plans.”

Hikma is pencilled in to post full year results for 2025 on 26 February 2026.

Read more

Monzo chair makes early exit after boardroom rift

The valuation would cement Monzo's status as one of Britain's biggest tech start-ups.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Pharma
  • Business

People & Organisations

  • CEO
  • ceo change
  • CEOs
  • Economy
  • FTSE
  • ftse 100
  • ftse 150
  • FTSE 250
  • FTSE 350
  • FTSE AIM
  • ftse all share
  • ftse shares
  • FTSE stocks
  • Hikma
  • london stock
  • London Stock Exchange
  • Pharma
  • pharma tariffs
  • pharmaceuticals
  • pharmacy
  • Profit
  • UK economy

Trending Articles

  • Jobless Banquet: Youth unemployment surge ‘sends Neets to KFC’

  • As it happened: FTSE 100 drops as oil prices rise after Trump makes Hormuz threat

  • US bond market jitters spark UK economy recession warning

  • Amanda Blanc has worked her magic at Aviva

  • City law firm sues prominent Emirati business family

More from Morning Wire

  • Diageo boss ‘drastic’ Dave Lewis eyes £20m pay deal as 2,000 jobs slashed

    Hospitality
    Dave Lewis, former Tesco CEO, smiling in a supermarket aisle with products on shelves
  • Monzo chair makes early exit after boardroom rift

    Fintech
    The valuation would cement Monzo's status as one of Britain's biggest tech start-ups.
  • Vistry angers market with £30m loss as new boss faces turbulent start

    Property
    Vistry Group headquarters building with modern architecture and corporate signage visible in a business district setting
  • Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

    Healthcare
    Hikma produces generic drugs
  • Ocado founder Steiner set to quit as boss after board coup

    Retail
    Ocado and Openreach lead push against Congestion charge for electric vans
  • JD assembles Ikea chair after rocky period for retailer

    Retail
    Peter Agnefjäll, former IKEA CEO, in a suit, headshot
  • Lucy Rigby back as City minister

    Politics
    Lucy Rigby, a blonde woman in glasses and a red blazer, with a phone in her pocket, walking past a black gate.
  • Rachel Reeves’ sister takes top legal role in Burnham’s Cabinet overhaul

    Politics
    Close-up of a business professionals hands typing on a laptop keyboard with financial charts on screen
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook